The area under the curve (AUC) score of ANKRD29 for predicting ICB effects of NSCLC was 0.7, which was better than TIDE, MSI and IFNG scores prediction efficiency and similar with CD274, CD8 and Merck18 scores (Fig. S4A) [38]. This evidence concerns the gene CD8A and non-small cell lung carcinoma.